About Us 
GreyB is a technology consulting firm that uses patents as a base to help clients in various spheres. By leveraging 

highly skilled humans with machine learning, it focuses on deriving hidden insights and uncovering difficult to reach 

conclusions. Since its inception in 2007, it has successfully completed over 2671 projects with more than 370 clients 

across 37 countries.  

What Makes Us Different?  

At GreyB, we take projects as a challenge rather than an assignment of hours. And while doing so, we try not to 

depend upon a preset methodology, but in each step, we innovate the search process, always and every time.  

GreyB Services   

GreyB Services © 2021     2 

 

List of 136 Drug Patents that Are Going to Expire Between 2021 - 2025 

 
Drug Patent Expiring in 2021 4 

Drug Patent Expiring in 2022 6 

Drug Patent Expiring in 2023 7 

Drug Patent Expiring in 2024 11 

Drug Patent Expiring in 2025 14 

 
 
 

   

GreyB Services © 2021     3 

 

Drug Patent Expiring in 2021 

Patents Expiring in 

Brand  Generic Name  Expiration Date  Company  Sales information 
2021 
BYSTOLIC  NEBIVOLOL  US6545040  December 17, 2021  ALLERGAN SALES LLC  $585.8 Million in 2018 

MERCK SHARP AND 

DOHME CORP   
CRIXIVAN  INDINAVIR  US6689761  February 10, 2021 
 

US6642245  May 04, 2021 

EMTRIVA  EMTRICITABINE  GILEAD SCIENCES INC   
US6703396  September 09, 2021 

US6733783 

US8361499 
HYSINGLA ER  HYDROCODONE ER  October 30, 2021  PURDUE PHARMA LP   
US8551520 

US8647667 

US6667344 

US6814953 

PERFOROMIST  FORMOTEROL  June 22, 2021  MYLAN SPECIALTY LP   

US7348362 

US7462645 

GreyB Services © 2021     4 

 

US8623922 

US9730890 

US6573293 
August 15, 2021 
SUTENT  SUNITINIB  US7125905  PFIZER  $264 Million in 2018 

US7211600  June 22, 2021 

US6750237 
ASTRAZENECA 
ZOMIG NS  ZOLMITRIPTAN  May 28, 2021   
PHARMACEUTICALS LP 
US7220767 

   

GreyB Services © 2021     5 

 

Drug Patent Expiring in 2022 

Brand  Generic Name  Patents Expiring in  Patent Expiration Date  Company  Sales information 
2022 
US6699871  July 26, 2022 
MERCK SHARP AND 
JANUVIA  SITAGLIPTIN  $3.68 Billion In 2018 
DOHME CORP 
US7125873  July 26, 2022 

PRISTIQ  DESVENLAFAXINE  US6673838  March 01, 2022  PFIZER  $206 Million in 2018 

US8557285  May 31, 2022 

US8852636  May 31, 2022 

US8858996  May 31, 2022 

ESOMEPRAZOLE/ 
VIMOVO  US9161920  May 31, 2022  PFIZER  $67.6 Million in 2018 
NAPROXEN 

US9198888  May 31, 2022 

US9345695  May 31, 2022 

US9707181  May 31, 2022 

VIMPAT  LACOSAMIDE  USRE38551  March 17, 2022  UCB INC.  €1.1 Billion in 2018 

   

GreyB Services © 2021     6 

 

Drug Patent Expiring in 2023 

Patents Expiring in 

Brand  Generic Name  Patent Expiration Date  Company  Sales information 
2023 
US7468390  November 27, 2023 

US8101659  NOVARTIS 
ENTRESTO  SACUBITRIL; VALSARTAN  PHARMACEUTICALS  $1.7 Billion 2018 
US8404744  July 14, 2023  CORP 

US8796331 

US7101993  September 05, 2023 

SPINRAZA  NUSINERSEN SODIUM  BIOGEN IDEC INC  $1.72 Billion in 2018 
US8110560  December 05, 2025 

US7015315  March 21, 2023 

AKCEA THERAPEUTICS  $2.2 Million in Q4 
TEGSEDI  INOTERSEN SODIUM 
INC  2018 
US7101993  September 05, 2023 

US6900175  December 25, 2023 

US7115564 
DALBAVANCIN 
DALVANCE  ALLERGAN SALES LLC  $81.9 Million in 2019 
HYDROCHLORIDE 
US7119061  November 14, 2023 

US8143212 

GreyB Services © 2021     7 

 

US8188276 
NOVARTIS 
ZYKADIA  CERITINIB  US8835430  January 31, 2023  PHARMACEUTICALS  $91 Million in 2016 
CORP 
US9018204 

NOVARTIS 
$330 Million in Q4 
PROMACTA  ELTROMBOPAG OLAMINE  US7160870  May 20, 2023  PHARMACEUTICALS 
2018 
CORP 

$142-$143 Million in 

RUBRACA  RUCAPARIB CAMSYLATE  US6495541  November 22, 2023  CLOVIS ONCOLOGY INC 
2019 

US7777050 

US8178693 
$35.1 Million in Q3 
MEKTOVI  BINIMETINIB  March 13, 2023  ARRAY BIOPHARMA INC 
2019 
US8193229 

US8513293 

US6900184 

PIPERACILLIN SODIUM,  WYETH 

ZOSYN  US7915229  April 14, 2023  $51 Million in 2019 
TAZOBACTAM SODIUM  PHARMACEUTICALS LLC 

US8133883 

US7192938 
HOFFMANN LA ROCHE 
BONIVA  IBANDRONATE SODIUM  May 06, 2023  $517 Million in 2011 
US7410957  INC 

GreyB Services © 2021     8 

 

US7718634 

NOVARTIS 
PAZOPANIB 
VOTRIENT  US7105530  October 19, 2023  PHARMACEUTICALS  $828 Million in 2018 
HYDROCHLORIDE 
CORP 

NOVARTIS 
TYZEKA  TELBIVUDINE  US7858594  September 11, 2023  PHARMACEUTICALS  - 
CORP 

AMLODIPINE BESYLATE;  US8101599  NOVARTIS 

EXFORGE  HYDROCHLOROTHIAZIDE;  May 16, 2023  PHARMACEUTICALS  $1.025 Billion in 2019 
VALSARTAN  US8475839  CORP 

US8034366 

US8034370 
January 09, 2023 
US9192511 

$33.7 Million in Q3 

OZURDEX  DEXAMETHASONE  US10076526  ALLERGAN INC 
2019 

US6899717  November 01, 2023 

US8506987 
January 09, 2023 
US10702539 

AMAG  $41.7 million in Q4 

FERAHEME  FERUMOXYTOL  US6599498  June 30, 2023 
PHARMACEUTICALS INC  2019 

GreyB Services © 2021     9 

 

US7977376  February 2, 2023  NOVARTIS 

OLOPATADINE 
PATANASE  PHARMACEUTICALS  - 
HYDROCHLORIDE 
US8399508  September 17, 2022  CORP 

US6987102 
$108.3 Million in 
MOZOBIL  PLERIXAFOR  July 22, 2023  GENZYME CORP 
2018 
US7897590 

US7229630  June 20, 2023 

SEPTODONT HOLDING 
ORAVERSE  PHENTOLAMINE MESYLATE  - 
SAS 
US7569230  October 17, 2023 

TRAMADOL  PURDUE PHARMA 

RYZOLT  US7988998  October 27, 2023  - 
HYDROCHLORIDE  PRODUCTS LP 

   

GreyB Services © 2021     10 

 

Drug Patent Expiring in 2024 

Patents Expiring in 

Brand  Generic Name  Patent Expiration Date  Company  Sales information 
2024 
MULPLETA  LUSUTROMBOPAG  US7601746  September 05, 2024  SHIONOGI INC  200 Million Yen in 2018 

CANAGLIFLOZIN;  US8785403  July 30, 2024  JANSSEN 

INVOKAMET XR  METFORMIN  PHARMACEUTICA $1.41 Billion in 2016 
HYDROCHLORIDE  US8222219  March 11, 2025  LS INC 

US7855217  November 24, 2024 

REVLIMID  LENALIDOMIDE  CELGENE CORP  $10.82 billion in 2019 
US7968569  October 07, 2023 

US7973031  October 17, 2024  NOVARTIS 

RYDAPT  MIDOSTAURIN  PHARMACEUTICA $150 Million in 2018 
US8222244  October 29, 2022  LS CORP 

US7196086 
MERCK SHARP 
PREVYMIS  LETERMOVIR  May 22, 2024  $370 Million in 2020 
AND DOHME CORP 
US8513255 

US7214695  April 27, 2024 

FOLDRX 
US7214696 
PHARMACEUTICA $259 million in Jan - 
VYNDAQEL  TAFAMIDIS MEGLUMINE  December 19, 2023 
LS INC SUB PFIZER  Sep 2019 
US8168663 
INC 

US8653119  January 28, 2024 

GreyB Services © 2021     11 

 

US7151102  April 29, 2022 

US7449464  ASTRAZENECA 
LYNPARZA  OLAPARIB  October 11, 2024  PHARMACEUTICA $847 Million in 2018 
US7981889  LS LP 

US8912187  March 12, 2024 

NOVARTIS 
NILOTINIB 
TASIGNA  US7169791  January 04, 2024  PHARMACEUTICA $1.88 Billion in 2019 
HYDROCHLORIDE 
LS CORP 

SUNOVION 
LEVALBUTEROL 
XOPENEX HFA  US7256310  October 08, 2024  PHARMACEUTICA $148 Million in 2012 
TARTRATE 
LS INC 

TEVA 
VANDAZOLE  METRONIDAZOLE  US7456207  September 22, 2024  PHARMACEUTICA - 
LS USA 

US8653033 
TERSERA 
PRIALT  ZICONOTIDE ACETATE  US8765680  October 10, 2024  THERAPEUTICS  $27 Million in 2017 
LLC 
US9707270 

US7947724 

PALONOSETRON  US7947725  HELSINN 

ALOXI  January 30, 2024  $459 Million in 2017 
HYDROCHLORIDE  HEALTHCARE SA 
US7960424 

GreyB Services © 2021     12 

 

US8518981 

US8598218 

US9173942 

US9439854 

US9457020 

   

GreyB Services © 2021     13 

 

Drug Patent Expiring in 2025 

Patents Expiring in 

Brand  Generic Name  Patent Expiration Date  Company  Sales information 
2025 
US7230098  August 26, 2025 
XALKORI  CRIZOTINIB  PFIZER  $524 Million in 2018 
US8785632  March 01, 2025 

US9566260 
July 11, 2025 
FRESENIUS KABI 
OMEGAVEN  FISH OIL TRIGLYCERIDES  US9629821  - 
USA LLC 

US10350186  November 05, 2024 

US7288657  December 23, 2025 

US7491736 

MYLAN IRELAND 
YUPELRI  REVEFENACIN  US7521041  $3.3 Million in Q4 2018 
LTD 
March 10, 2025 
US7550595 

US7585879 

BRISTOL MYERS 
SPRYCEL  DASATINIB  US8680103  February 04, 2025  $2 Billion in 2018 
SQUIBB CO 

US7417148  December 11, 2025 

BOSUTINIB 
BOSULIF  PF PRISM CV  $477 Million in 2019 
MONOHYDRATE  US7767678  November 23, 2026 

GreyB Services © 2021     14 

 

US7919625  December 11, 2025 

ISAVUCONAZONIUM  ASTELLAS PHARMA  $180 Million from July 

CRESEMBA  US6812238  October 31, 2025 
SULFATE  US INC  2018 to June 2019 

ANTARA  FENOFIBRATE  US8026281  April 22, 2025  LUPIN INC  $70 Million in 2008 

US7947739 

US8022106 

US8273795 

US8487005  AMRING 
LYSTEDA  TRANEXAMIC ACID  March 04, 2025  PHARMACEUTICALS  $25 Million in 2012 
US8791160  INC 

US8809394 

US8957113 

US9060939 

US8784789  January 13, 2025 

BAUSCH AND LOMB 
BEPREVE  BEPOTASTINE BESILATE  $160.3 Million in 2011 
INC 
US8877168  July 30, 2023 

SANCUSO  GRANISETRON  US7608282  January 22, 2025  KYOWA KIRIN INC  - 

TAPENTADOL  COLLEGIUM 
NUCYNTA  US7994364  June 27, 2025  $46.8 Million in 2019 
HYDROCHLORIDE  PHARMACEUTICAL 

GreyB Services © 2021     15 

 

INC 

BEMPEDOIC ACID,  ESPERION 

NEXLIZET  US7335799  December 03, 2025  - 
EZETIMIBE  THERAPEUTICS INC 

   

GreyB Services © 2021     16 

 

If it exists, we will find it.  

That’s the philosophy that drives us and helps us go above and beyond on all the projects that we work on. 
You can say - ​It’s in the culture.  

And if that’s something you’re looking for in a search partner too. I think we’ll make a good team. Let’s get in 
touch and explore how we can help you get the maximum value out of your patents.  

Talk to me directly at -   We are also available on call-  

Deepak Syal - ​[email protected]    Singapore: +65 84306322 

Or my partner at -   United States: +1 202-455-5058 

Chakshu Kalra - ​[email protected]   India: +91 9878711122 

GreyB Services © 2021     17